BCOR Overexpression in Renal Malignant Solitary Fibrous Tumors: A Close Mimic of Clear Cell Sarcoma of Kidney.


Journal

The American journal of surgical pathology
ISSN: 1532-0979
Titre abrégé: Am J Surg Pathol
Pays: United States
ID NLM: 7707904

Informations de publication

Date de publication:
06 2019
Historique:
pubmed: 14 3 2019
medline: 19 2 2020
entrez: 14 3 2019
Statut: ppublish

Résumé

BCOR immunoreactivity is a sensitive and highly specific marker for clear cell sarcoma of the kidney (CCSK). However, a subset of adult renal sarcomas which overexpress BCOR are negative for BCOR genetic alterations, including BCOR gene fusions or BCOR-internal tandem duplication, and thus remain unclassified. We report 5 such undifferentiated renal/perirenal sarcomas which raised the differential diagnosis of CCSK due to their morphologic appearance and strong BCOR immunoreactivity, but which on RNA sequencing proved to be malignant solitary fibrous tumors (SFTs). The neoplasms occurred in patients at an age range of 30 to 62 years. Three patients were females and 2 male. Four were primary renal neoplasms while one was perirenal. All 5 neoplasms were cellular, nonpleomorphic, undifferentiated sarcomas with branching capillary vasculature composed of primitive round to ovoid neoplastic cells with scant cytoplasm and nuclei having fine, evenly dispersed chromatin. None of the cases demonstrated the typical hyperchromatic fusiform nuclei, prominent collagen deposition, or hemangiopericytomatous vasculature of SFT. All 5 cases were strongly immunoreactive for BCOR. Three cases were CD34 negative, where the other 2 were only focally CD34 positive. STAT6 was subsequently found to be positive by immunohistochemistry in all 5 cases. In summary, we report a previously unrecognized mimic of CCSK: malignant SFTs with an undifferentiated/small round cell phenotype along with branching capillary vasculature, strong immunoreactivity for BCOR, and minimal or no immunoreactivity for CD34. As CCSK is treated with a specific chemotherapy regimen, this distinction has therapeutic implications.

Identifiants

pubmed: 30864973
doi: 10.1097/PAS.0000000000001243
pmc: PMC6520176
mid: NIHMS1522018
doi:

Substances chimiques

BCOR protein, human 0
Biomarkers, Tumor 0
Proto-Oncogene Proteins 0
Repressor Proteins 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

773-782

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA140146
Pays : United States

Références

Am J Surg Pathol. 2018 Aug;42(8):1128-1131
pubmed: 29851702
Diagn Pathol. 2011 Oct 05;6:96
pubmed: 21970525
Am J Surg Pathol. 2009 Sep;33(9):1314-21
pubmed: 19718788
Case Rep Nephrol Urol. 2013 Jan;3(1):1-8
pubmed: 23466873
J Pathol. 2016 Apr;238(5):617-20
pubmed: 27000436
Genes Chromosomes Cancer. 2014 May;53(5):381-91
pubmed: 24488803
Am J Surg Pathol. 2018 Apr;42(4):553-560
pubmed: 29309307
Urol Case Rep. 2015 Oct 17;4:45-7
pubmed: 26793578
Int J Surg Pathol. 2018 Aug;26(5):423-427
pubmed: 29482421
J Pathol. 2010 Jul;221(3):300-7
pubmed: 20527023
Am J Surg Pathol. 1989 Aug;13(8):640-58
pubmed: 2665534
Arch Pathol Lab Med. 2006 Jun;130(6):857-61
pubmed: 16740040
Int J Clin Exp Pathol. 2014 May 15;7(6):2737-42
pubmed: 25031693
Am J Surg Pathol. 2000 Jan;24(1):4-18
pubmed: 10632483
Pathology. 2017 Oct;49(6):671
pubmed: 28822554
Onco Targets Ther. 2014 May 08;7:679-85
pubmed: 24855378
J Clin Pathol. 2017 Jun;70(6):508-514
pubmed: 27802414
Int J Surg Pathol. 2016 Jun;24(4):281-92
pubmed: 26811389
Am J Pathol. 2014 Apr;184(4):1209-1218
pubmed: 24513261
Int J Clin Exp Pathol. 2013 Dec 15;7(1):386-93
pubmed: 24427361
Am J Surg Pathol. 2000 Aug;24(8):1087-96
pubmed: 10935649
Nat Commun. 2015 Nov 17;6:8891
pubmed: 26573325
Cancer Med. 2016 Feb;5(2):159-68
pubmed: 26686340
Am J Surg Pathol. 2000 Jul;24(7):917-26
pubmed: 10895814
Am J Surg Pathol. 2014 Apr;38(4):552-9
pubmed: 24625420
Am J Surg Pathol. 2012 Aug;36(8):1202-15
pubmed: 22613995
Eur J Cancer. 2012 Sep;48(14):2219-26
pubmed: 22579455
Am J Surg Pathol. 2017 Dec;41(12):1702-1712
pubmed: 28817404
Ann Diagn Pathol. 2013 Oct;17(5):457-63
pubmed: 23040384
J Pathol. 2012 May;227(1):72-80
pubmed: 22294382
Mod Pathol. 2000 Jan;13(1):29-36
pubmed: 10658907
Nat Genet. 2012 Mar 04;44(4):461-6
pubmed: 22387997
Oncotarget. 2015 Dec 1;6(38):40934-9
pubmed: 26516930
Mod Pathol. 2014 Mar;27(3):390-5
pubmed: 24030747
Aktuelle Urol. 2012 Jan;43(1):59-62
pubmed: 22271338
Mod Pathol. 2017 Oct;30(10):1433-1442
pubmed: 28731041
Am J Surg Pathol. 2018 May;42(5):604-615
pubmed: 29300189
Am J Surg Pathol. 2016 Dec;40(12):1670-1678
pubmed: 27428733
Nat Genet. 2015 Aug;47(8):861-3
pubmed: 26098867
Oncol Lett. 2012 Nov;4(5):993-995
pubmed: 23162638
Proc Natl Acad Sci U S A. 2012 Jan 17;109(3):929-34
pubmed: 22223660
Am J Surg Pathol. 2015 Mar;39(3):365-73
pubmed: 25353281
Urol Int. 2013;91(4):373-83
pubmed: 24008397
Genes Chromosomes Cancer. 2016 Feb;55(2):120-3
pubmed: 26493387

Auteurs

Pedram Argani (P)

Departments of Pathology and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD.

Yu-Chien Kao (YC)

Department of Pathology, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan.

Lei Zhang (L)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.

Yun-Shao Sung (YS)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.

Rita Alaggio (R)

University of Pittsburgh School of Medicine, Pittsburgh, PA.

David Swanson (D)

Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada.

Andres Matoso (A)

Departments of Pathology and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD.

Brendan C Dickson (BC)

Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada.

Cristina R Antonescu (CR)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH